Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study.

Delphine Casabonne, Yolanda Benavente, Julia Seifert, Laura Costas, María Armesto, María Arestin, Caroline Besson, Fatemeh S. Hosnijeh, Eric J. Duell, Elisabete Weiderpass, Giovanna Masala, Rudolf Kaaks, Federico Canzian, María-Dolores Chirlaque, Vittorio Perduca, Francesca R. Mancini, Valeria Pala, Antonia Trichopoulou, Anna Karakatsani, Carlo La VecchiaMaria-Jose Sánchez, Rosario Tumino, Marc J. Gunter, Pilar Amiano, Salvatore Panico, Carlotta Sacerdote, Julie A. Schmidt, Heiner Boeing, Matthias B. Schulze, Aurelio Barricarte, Elio Riboli, Anja Olsen, Anne Tjønneland, Roel Vermeulen, Alexandra Nieters, Charles H. Lawrie, Silvia de Sanjosé

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic lymphocytic leukemia (CLL) is an incurable disease accounting for almost one-third of leukemias in the Western world. Aberrant expression of microRNAs (miRNAs) is a well-established characteristic of CLL, and the robust nature of miRNAs makes them eminently suitable liquid biopsy biomarkers. Using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), the predictive values of five promising human miRNAs (hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p), identified in a pilot study, were examined in serum of 224 CLL cases (diagnosed 3 months to 18 years after enrollment) and 224 matched controls using Taqman based assays. Conditional logistic regressions were applied to adjust for potential confounders. The median time from blood collection to CLL diagnosis was 10 years (p25-p75: 7-13 years). Overall, the upregulation of hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p was associated with subsequent risk of CLL [OR(1∆Ct-unit increase) (95 = 1.42 (1.18-1.72), 1.64 (1.31-2.04) and 1.75 (1.31-2.34) for hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p, respectively] and the strongest associations were observed within 10 years of diagnosis. However, the predictive performance of these miRNAs was modest (area under the curve textless0.62). hsa-miR-16-5p and hsa-miR-223-3p levels were unrelated to CLL risk. The findings of this first prospective study suggest that hsa-miR-29a, hsa-miR-150-5p and hsa-miR-155-5p were upregulated in early stages of CLL but were modest predictive biomarkers of CLL risk.
Original languageEnglish
JournalInternational Journal of Cancer
Issue number5
Publication statusPublished - Sep 1 2020

Fingerprint Dive into the research topics of 'Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study.'. Together they form a unique fingerprint.

Cite this